House of Delegates today passed the Endocrine Society's resolution to improve access to anti-obesity medications.

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

High-demand obesity treatments will not be covered under the federal government’s Medicare program, it was announced Friday. The Centers for Medicare and Medicaid Services said late Friday that ...

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid ...

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.

As a physician assistant in Charlotte, I have witnessed firsthand the transformative impact of new obesity medications on ...

Adolescents face significant barriers to obesity medication access, despite a surge in prescriptions. Discover the ...

Low-income Pennsylvanians could lose access to medical coverage for popular weight-loss drugs like Ozempic and Wegovy as ...

The National Council on Aging (NCOA), the national voice for every person's right to age well, applauds today's ...

Thousands of New York residents are waiting for a kidney transplant, and a long-delayed state program could soon spur more ...

My years dedicated to patient care have provided a deep understanding of the profound impact obesity has on individuals' ...

In South Carolina, the state Medicaid agency estimates only 1,300 beneficiaries will meet the stringent prerequisites for GLP ...